ClinicalTrials.gg
RecruitingNCT07560696CognishineUpdated May 1, 2026

Feasibility of Web-based Therapy Sessions

An interventional study of a Web-Based Platform for delivering treatment for cognitive and language impairment amongst adults with acquired neurological disorders in Cognitive Impairment, Speech Dysfunction and Acquired Brain Injury, sponsored by Liverpool University Hospitals NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Liverpool University Hospitals NHS Foundation Trust · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 6 months after the study started (first participant enrolled Jul 2024, registered Jan 2026).
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 138 studies in Cognitive Dysfunction with a site in United Kingdom — 37 open to participants now, 54 under way, 7 of them phase 3. Cognitive Dysfunction · United Kingdom.

Planned enrollment
43rd of 89
80 · median 70
Started
2024
with 9 others
No phase
51 of 138
15 open now
Primary completion
2026-07
later than 23 of 53 live
Registered
130th of 138
by date

Among the 138 studies in Cognitive Dysfunction with a site in United Kingdom, this one is the 43rd largest by planned enrollment of the 89 interventional ones that give a count, is one of 10 that started in 2024, is one of 51 with no phase, reaches primary completion later than 23 of the 53 other live ones, and was the 130th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

37 of the 138 studies in Cognitive Dysfunction with a site in United Kingdom are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Cognitive Dysfunction with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this feasibility study is to explore rehabilitation outcomes, usability and user experience of a web-based platform for delivering treatment for cognitive and language impairment amongst adults with acquired neurological disorders in critical illness and stroke disorders.

The main question it aims to answer is:

" Is it feasible to use a web-based platform for delivering rehabilitation treatment in a large acute National Health Care Organisation"

Participants will undergo therapy sessions prescribed by therapists on a web-based platform instead of the conventional paper-based therapy sessions for their cognitive and speech rehabilitation needs.

Read the detailed description

The population group will be adult patients admitted to critical care unit and stroke unit and diagnosed to have speech and cognitive impairment.

The intervention is to provide therapy prescribed by therapist through Cognishine, a web-based platform instead of paper-based therapy session.

The primary objective is to assess feasibility of using the Cognishine web-based platform in a large NHS Trust in acute care setting measured by number of completed therapy sessions, per patient days.

03

Conditions studied

  • Cognitive Impairment
  • Speech Dysfunction
  • Acquired Brain Injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with cognitive impairment and/or speech impairment being treated at the LUHFT Intensive Care Units and the Stroke wards
  • Need for Cognitive and/or speech and Language rehabilitation

Exclusion criteria

Exclusion Criteria:

  • Inability to obtain consent
  • Refusal to take part in the study
  • Failure to engage with the Cognishine platform
  • Inability to operate a mobile device/ tablet with support
  • Unavailability of study therapist to provide training of patients
  • Unstable medical condition
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Web-based patient-led therapy sessions

    All patients will receive standard of care rehabilitation. In addition, patients recruited into the study will use the Cognishine platform for cognitive and/or language rehabilitation

    Behavioral: a Web-Based Platform for delivering treatment for cognitive and language impairment amongst adults with acquired neurological disorders

Interventions

  • Behaviorala Web-Based Platform for delivering treatment for cognitive and language impairment amongst adults with acquired neurological disorders

    The Cognishine platform is a digital (web-based) general health and wellness monitoring platform. It is designed to support health care professionals specialised in rehabilitation of patients with neurological disorders, through a wide range of multi-media based generalised activities across speech, language, social-emotional, and cognition.

06

What researchers measure

Primary outcomes

  1. To assess the feasibility of using the Cognishine web-based platform in a large NHS Trust in acute care setting.

    Total number of completed sessions per patient on the cognishine platform

    Time frame: From recruitment until discharge from rehabilitation therapy or discharge from hospital, which ever comes first. Time frames will vary dependent on patient recovery .The anticipated time frame is 1 to 6 months. Maximum follow up is 12 months.

Secondary outcomes

  1. To assess staff and patient experience of using the Cognishine platform during therapy sessions.

    Patients \& therapists will be asked to complete the Mobile Health App Usability Questionnaire (MAUQ)for Interactive Mobile Health Apps used by patients. The questionnaire is designed and validated to evaluate the usability of interactive health apps from the users perspective. The MAUQ questionnaire comprises of 21 questions which cover 3 main usability domains. 1. Ease of use-Navigation, learnability and clarity. 2. Interface and satisfaction-Visual appeal, confidence and overall satisfaction. 3. Usefulness-Perceived value and effectiveness in helping users achieve their health goals. Scoring is via a 7 point Likert scale (1 - strongly disagree, 2 - disagree, 3 - somewhat disagree, 4 - neither agree nor disagree, 5 - somewhat agree, 6 -agree, 7 - strongly agree.),with higher scores indicating greater usability and satisfaction.

    Time frame: Patients will be asked to complete this on discharge from hospital. Therapists will be asked to complete the questionnaire one month after starting the study (in the middle of recruitment)

  2. To generate qualitative data about how to improve the end user experience for therapist to target barriers to implementation

    Focus groups composed of therapists who have used the platform will be asked to provide end user information about using the system. This qualitative data will be used to improve the platform.

    Time frame: 12 month into the study.

  3. To generate preliminary data on the rehabilitation progress associated with the use of the Cognishine platform.

    The Montreal Cognitive Assessment (MoCA) is a standard clinical measurement tool. The tool comprises assessment of visuospatial/executive functions ,naming, memory, attention, language ,abstraction and orientation. The scoring range is 0-30,with higher scores indicating better cognition, scores of \<26 indicating possible cognitive impairment. Scores will be collected from clinical notes at initial assessment and at discharge from rehabilitation therapy.

    Time frame: As recovery is highly individualised time frames will vary amongst participants .It is anticipated that the time frame will range from 1 to 6 months.

  4. To generate preliminary data on the rehabilitation progress associated with the use of the Cognishine platform.

    The Oxford Cognitive Screen(OCS) is specifically for stroke patients and reduces visual or language bias. It assesses attention, executive function, memory, language, number processing and praxis. Each domain is scored with results interpreted as impaired or not impaired. Scores from clinical notes will be collected at initial assessment and at discharge from rehabilitation therapy.

    Time frame: As recovery is highly individualised time frames will vary amongst participants .It is anticipated that the time frame will range from 1 to 6 months

  5. To generate preliminary data on the rehabilitation progress associated with the use of the Cognishine platform.

    The Orientation log(O-Log) score measures orientation, time place and situation. 10 items are measured , with each item scoring 0-3.The scoring range is 0-30,with higher scores reflecting better function. Scores \<25 indicate disorientation. Scores will be collected at initial assessment and at discharge from rehabilitation therapy

    Time frame: As recovery is highly individualised time frames will vary amongst participants .It is anticipated that the time frame will range from 1 to 6 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2026, 23 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 23 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2026
First posted
May 1, 2026
StartActual
Jul 3, 2024
Primary completionEst.
Jul 1, 2026
CompletionEst.
Jul 1, 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07560696
Lead sponsor
Liverpool University Hospitals NHS Foundation Trust
Collaborators
Israel Innovation Authority
Responsible party
Sponsor
First posted
May 1, 2026
Start date
Jul 3, 2024
Primary completion
Jul 1, 2026 (estimated)
Completion
Jul 1, 2026 (estimated)
Last update
May 1, 2026

Study contacts

Vinoth Sankar
Contact
Vinoth.Sankar@liverpoolft.nhs.uk
+044 0151 706 2000
Matthew Noonan
study chair · Liverpool University Hospitals NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion